BCGP & CPE Registration
CPE Only Registration
BCGP & CPE: $14 for Members, $22 for Non-Members
CPE Only: Free for Members, $10 for Non-Members
Antoine T. Jenkins, PharmD, BCPS
Clinical Associate Professor
Chicago State University, College of Pharmacy
Internal Medicine Clinical Pharmacist
Ingalls Memorial Hospital
Despite medical advancements and an improved comprehension of heart failure (HF),it continues to have a significant strain on the US healthcare system.The elderly population continues to be impacted at disproportionate rates.While research is robust regarding the management of heart failure with reduced ejection fraction, this is not the same for heart failure with preserved ejection fraction (HFpEF). This scarcity of data regarding HFpEF represents a major dilemma as patients with advanced age are oftentimes affected, unfortunately leaving clinicians with limited treatment options. Treatment guidelines advocate for the use of guideline-directed medical therapy in all patients (assuming no contraindications or severe intolerances), appropriate nonpharmacologic measures, and emphasizes the importance of effective care transitions. However, the elderly are acknowledged in current guideline statements only to a minor degree; thus, this limited recognition fails to provide much direction in terms of managing this population. Being medication experts, pharmacists play a significant role in ensuring that key therapies are utilized and can assist with bridging any gaps of knowledge as it relates to drug therapy. Medication regimens can be complex due to the presence of multiple other comorbidities; thus, our drug knowledge becomes an invaluable asset when assisting other members of the healthcare team. Additionally, with new pharmacologic entities now available, pharmacists can serve as initial contacts should any questions arise regarding appropriate patient selection. The aims of this webinar will be to educate attendees on updated treatment strategies, to discuss any unique considerations which can affect HF patients of advanced age, and to design an overall treatment plan for a given patient case.
At the conclusion of this application-based activity, participants should be able to:
- Compare and contrast therapeutic recommendations from nationally published guidelines regarding chronic HF management.
- Discuss newer therapies specifically indicated for chronic HF treatment and their potential role in the elderly.
- Describe unique circumstances faced by the geriatric HF patient.
- Given a patient case, design an appropriate pharmacotherapeutic plan for the geriatric HF patient.